Company Overview

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable.

The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.

Stock Data

MTNB Symbol
NYSE American Market
Market Cap

Upcoming Events

2017 Financial Results and Corporate Update Conference Call and Webcast

To participate in the call, please dial (877) 407-5976 (domestic) or (412) 902-0031 (international).